Phase 2 Cystic Fibrosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with cystic fibrosis
- People aged 12 years or older
- People who have been taking the medication elexacaftor/tezacaftor/ivacaftor (also known as Trikafta) consistently for at least 90 days before joining the trial
- People whose sweat chloride level is 50 mmol/L or higher while taking elexacaftor/tezacaftor/ivacaftor (this is a specific measurement from a sweat test)
Who may not be able to join:
- People who have previously had a lung transplant
- People with a BMI (body mass index) below 18
- People who have had a cystic fibrosis lung flare-up requiring a hospital stay or intravenous (IV) antibiotics in the past 30 days
- People who have used steroid tablets or regular anti-inflammatory medications (such as ibuprofen) in the past 30 days
- People who regularly take a type of blood pressure medication known as angiotensin receptor blockers (ARBs) or ACE inhibitors
- People currently taking medications known to interact with losartan, including a drug called aliskiren
- People with significant ongoing kidney problems (confirm with trial site for exact measurement)
- People who are pregnant or breastfeeding
- Females of childbearing age who are unable or unwilling to use an approved method of contraception during the study
- People who, in the trial doctor's judgement, have a serious health condition or abnormal test results that could make participation risky or unsuitable
- People already taking part in another clinical trial that the trial doctor believes could affect the results of this study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Charles Bengtson, MD, MSc, University of Kansas Medical Center
Phone: 9135886045
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sweat chloride
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.